Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up

Huan Tao, Nenggang Jiang, Yongqian Jia · 2026

Read Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up by Huan Tao, Nenggang Jiang, Yongqian Jia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594707.txt.

Description

Huan Tao, Nenggang Jiang, and Yongqian Jia follow a stubborn blood disorder held in check for six years by one epigenetic drug. The patient has T-cell large granular lymphocyte leukemia with pure red cell aplasia: the marrow stops making red cells. Standard immune suppression with cyclosporine failed. Their 2026 case turns to chidamide, a histone-targeting drug, first paired with thalidomide. Control came quickly. Thalidomide was later dropped, and chidamide alone kept the remission.

A clonal T-cell population persisted on flow tests the whole time. Remission here means the blood counts behave, not that the clone vanished. The team offers chidamide as a convenient salvage option where no standard exists. One case cannot set policy, but six quiet years argue loudly.

Catalog record

CREATORHuan Tao, Nenggang Jiang, Yongqian Jia
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE17 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13594707

Browse the full library · About the Tower of Babel